Levofloxacin Hydrochloride Tablets

This product is the levorotatory form of ofloxacin, and its antibacterial activity is about twice that of ofloxacin. Its main mechanism of action is to inhibit the activity of bacterial DNA gyrase (bacterial topoisomerase II) and hinder bacterial replication to achieve antibacterial effect. This product has the characteristics of a broad antibacterial spectrum and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Escherichia coli, Klebsiella, Serratia, Proteus, Shigella, Salmonella, Citrobacter, Acinetobacter, as well as Gram-negative bacteria such as Pseudomonas aeruginosa, Haemophilus influenzae, and gonorrhea. It also has good antibacterial effects on some methicillin-sensitive Staphylococci, Streptococcus pneumoniae, Streptococcus pyogenes, hemolytic Streptococci, and Legionella, Mycoplasma, Chlamydia, etc. However, it has poor effects on anaerobic bacteria and enterococci.

Levofloxacin hydrochloride. Chemical name: (S)-(-)-9-Fluoro-2.3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-fluoro-7H-pyridine.

This product is a white film-coated tablet, which appears off-white or light yellow after removing the film.

This product is suitable for the following mild and moderate infections caused by sensitive bacteria; respiratory system infections: acute bronchitis, acute exacerbation of chronic bronchitis, diffuse bronchiolitis, bronchiectasis and infection, pneumonia, tonsillitis (peritonsillar abscess); urinary system infections: pyelonephritis, complicated urinary tract infection, etc.; reproductive system infections: acute prostatitis, acute epididymitis, uterine cavity infection, uterine adnexitis, pelvic inflammatory disease (metronidazole can be used in combination when anaerobic infection is suspected); skin and soft tissue infections: infectious impetigo, cellulitis, lymphangiitis (nodal inflammation), subcutaneous abscess, perianal abscess, etc.; intestinal infections: bacillary dysentery, infectious enteritis, salmonella enteritis, typhoid and paratyphoid; various infections in patients with sepsis, neutropenia and immunodeficiency; other infections: mastitis, trauma, burns and postoperative wound infection, abdominal cavity infection (metronidazole can be used in combination when necessary), cholecystitis, cholangitis, bone and joint infection and ENT infection, etc.

Oral administration: 0.1-0.2g per time for adults, twice a day. For patients with severe conditions, it can be increased to three times a day.

Adverse reactions may occur during the use of levofloxacin hydrochloride: Digestive system: sometimes nausea, vomiting, abdominal discomfort, diarrhea, loss of appetite, abdominal pain, indigestion, etc.; Allergies: Occasionally edema, urticaria, fever, photosensitivity, and sometimes rash, itching, erythema, etc.; Nervous system: Occasionally tremor, numbness, visual abnormalities, tinnitus, hallucinations, drowsiness, and sometimes insomnia, dizziness, headache, etc.; Kidney: Occasionally increase in blood urea nitrogen; Liver: Transient liver function abnormalities may occur, such as increased serum transaminase and increased serum total bilirubin; Blood: Sometimes anemia, leukopenia, thrombocytopenia, and eosinophilia may occur; The incidence of the above adverse reactions is between 0.1 and 5%, which are generally tolerated and disappear quickly after the end of the course of treatment. If abnormalities are found, they should be observed carefully, and if necessary, the medication can be stopped and appropriate treatment can be carried out.

It is contraindicated for patients who are allergic to quinolones, pregnant or lactating women, and patients under 18 years of age.

Precautions for children: Patients under 18 years old are prohibited from using this product. Precautions for pregnancy and lactation: Precautions for pregnant and lactating women are prohibited from using this product. Precautions for the elderly: Elderly patients often have impaired renal function. Since this product is partially excreted through the kidneys, it needs to be used in a reduced dose.

When this product is used simultaneously with antacids containing magnesium or aluminum, sucralfate, metal cations (such as iron), and zinc-containing multivitamin preparations, it will interfere with the absorption of this product by the gastrointestinal tract, causing the concentration of this drug in various systems to be significantly reduced. Therefore, the time of taking the above-mentioned drugs should be at least 2 hours before or after using this product. Avoid using it simultaneously with theophylline. If it is necessary to use it simultaneously, the blood concentration of theophylline should be monitored and the dosage should be adjusted accordingly. When used simultaneously with warfarin or its derivatives, the prothrombin time or other coagulation tests should be monitored. When used simultaneously with non-steroidal anti-inflammatory drugs, there is a possibility of inducing convulsions. When used simultaneously with oral hypoglycemic drugs, it may cause blood sugar disorders, including hyperglycemia and hypoglycemia. Therefore, blood sugar concentrations should be monitored during medication. Once hypoglycemia occurs, this product should be discontinued immediately and appropriate treatment should be given.

Keep away from light and store in sealed container.

0.1g (based on C18H20FN3O4)

24 months

Dingfukang Pharmaceutical Co., Ltd.

• Founded in:

  2003-06-23

• Address:

  No. 1 Lianbo Avenue, Queshan County, Henan Province

• Tax NO.:

  91411700745750818R

• Registered Funds:

  60 million yuan

• Email:

  Log in to view